Want to see HK:0574 full AI Analyst Report?
0574 Stock Chart & Stats
HK$0.05
<HK$0.01(2.04%)
At close: 4:00 PM EST
HK$0.05
<HK$0.01(2.04%)
Day’s Range― - ―
52-Week RangeHK$0.02 - HK$0.06
Previous CloseN/A
Volume290.00K
Average Volume (3M)0.00
Market Cap
HK$35.83M
Enterprise ValueHK$281.96
Total Cash (Recent Filing)HK$5.53M
Total Debt (Recent Filing)HK$205.79M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield7.65%
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,990,576,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.16
Price to Book (P/B)-0.36
Price to Sales (P/S)0.61
P/FCF Ratio-4.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Operating ProfitabilityPositive operating profit and EBITDA in 2025 indicate that the core business can generate operating earnings under improved conditions. Although profitability remains thin and has not reached the bottom line, this provides a foundation for potential earnings repair if operating performance is sustained.
Debt ReductionMaterial debt reduction versus 2023 is a constructive balance-sheet development because it can lower financing pressure and improve financial flexibility. The benefit is constrained by negative equity and continuing solvency risk, but lower debt may support stabilization if cash losses moderate.
Prior Earnings ReboundThe 2023 rebound, which included revenue growth and positive net income, demonstrates that the company has previously been able to improve its financial performance. This suggests some earnings recovery potential, though the later return to losses means the improvement was not yet durable.
Bears Say
Persistent Negative EquityPersistently negative shareholders’ equity is a major solvency weakness and leaves the company with limited financial flexibility. It can restrict access to funding, increase dependence on creditors or asset disposals, and make the business more vulnerable if losses or cash needs continue.
Structural Cash ConsumptionNegative operating and free cash flow across every year shown indicates that reported operations have not consistently funded the business. Ongoing cash consumption can increase reliance on external financing or asset sales, limiting investment capacity and weakening resilience over the next several quarters.
Unstable Revenue And LossesRevenue volatility and renewed contraction in 2024–2025 weaken visibility into the company’s earnings base. Recurring net losses show that the business has not converted operations into dependable profitability, making margin recovery and sustainable growth difficult to establish.
Pa Shun International Holdings Limited News
0574 FAQ
What was Pa Shun International Holdings Limited’s price range in the past 12 months?
Pa Shun International Holdings Limited lowest stock price was HK$0.02 and its highest was HK$0.06 in the past 12 months.
What is Pa Shun International Holdings Limited’s market cap?
Pa Shun International Holdings Limited’s market cap is HK$35.83M.
When is Pa Shun International Holdings Limited’s upcoming earnings report date?
Pa Shun International Holdings Limited’s upcoming earnings report date is Apr 01, 2027 which is in 185 days.
How were Pa Shun International Holdings Limited’s earnings last quarter?
Pa Shun International Holdings Limited released its earnings results on Mar 30, 2026. The company reported -HK$0.004 earnings per share for the quarter.
Is Pa Shun International Holdings Limited overvalued?
According to Wall Street analysts Pa Shun International Holdings Limited’s price is currently Overvalued.
Does Pa Shun International Holdings Limited pay dividends?
Pa Shun International Holdings Limited pays a Monthly dividend of HK$0.023 which represents an annual dividend yield of 7.65%. See more information on Pa Shun International Holdings Limited dividends here
What is Pa Shun International Holdings Limited’s EPS estimate?
Pa Shun International Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pa Shun International Holdings Limited have?
Pa Shun International Holdings Limited has 1,990,576,000 shares outstanding.
What happened to Pa Shun International Holdings Limited’s price movement after its last earnings report?
Pa Shun International Holdings Limited reported an EPS of -HK$0.004 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Pa Shun International Holdings Limited?
Currently, no hedge funds are holding shares in HK:0574
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pa Shun International Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.13%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pa Shun International Holdings Limited
Pa Shun International Holdings Limited, an investment holding company, engages in the pharmaceutical distribution and manufacturing businesses in the People's Republic of China. The company sells pharmaceutical products to wholesalers, hospitals, and other medical institutions in rural areas. It also sells pharmaceutical products manufactured by the company. The company was formerly known as Pa Shun Pharmaceutical International Holdings Limited and changed its name to Pa Shun International Holdings Limited in June 2017. The company was incorporated in 2011 and is headquartered in Wan Chai, Hong Kong. Pa Shun International Holdings Limited operates as a subsidiary of Praise Treasure Limited.
Technical Analysis
Beijing Tong Ren Tang Chinese Medicine Co
―
Tianda Pharmaceuticals Ltd.
―
Wai Yuen Tong Medicine Holdings Limited
―
Lee's Pharmaceutical Holdings Limited
―
Pak Fah Yeow International Limited
―